<div id="readability-page-1"><p>Precigen, Inc. (NASDAQ:PGEN - Get Free Report) gapped down before the market opened on Tuesday following insider selling activity. The stock had previously closed at $4.38, but opened at $4.17. Precigen shares last traded at $4.03, with a volume of 247,150 shares.</p><p>Specifically,  Director Randal J. Kirk sold 1,900,036 shares of the business's stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $4.18, for a total value of $7,942,150.48. Following the completion of the transaction, the director owned 341,189 shares of the company's stock, valued at approximately $1,426,170.02. The trade was a 84.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. </p><h2>Analyst Ratings Changes</h2><p>A number of research analysts have recently commented on the stock. Wall Street Zen cut shares of Precigen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 15th. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Precigen in a report on Wednesday, October 8th. Finally, HC Wainwright increased their price objective on Precigen from $8.50 to $9.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, November 14th. Four equities research analysts have rated the stock with a Buy rating, one  has given a Hold rating and one  has given a Sell rating to the company's stock. According to MarketBeat, Precigen presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $8.50.</p><p><b>Check Out Our Latest Report on PGEN</b></p><h2>Precigen Trading Down 8.0%</h2><p>The firm has a fifty day moving average price of $3.94 and a 200 day moving average price of $3.08. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -2.90 and a beta of 1.16. The company has a debt-to-equity ratio of 2.22, a quick ratio of 3.95 and a current ratio of 4.04. </p><p>Precigen (NASDAQ:PGEN - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.03). The business had revenue of $2.92 million during the quarter, compared to the consensus estimate of $0.67 million. Precigen had a negative net margin of 3,912.92% and a positive return on equity of 1,066.10%.  As a group, equities analysts predict that  Precigen, Inc. will post -0.32 EPS for the current fiscal year. </p><h2>Institutional Trading of Precigen</h2><p>Large investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd acquired a new position in  Precigen during the third quarter worth $39,000.  Russell Investments Group Ltd. bought a new position in  Precigen during the third quarter worth about $41,000.  Vontobel Holding Ltd. purchased a new position in  Precigen during the 3rd quarter valued at about $48,000.  CIBC Bancorp USA Inc. bought a new position in shares of  Precigen in the third quarter worth $53,000.  Finally, Voya Investment Management LLC raised its stake in  Precigen by 142.9% in the first quarter. Voya Investment Management LLC now owns 36,771 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 21,633 shares in the last quarter. 33.51% of the stock is currently owned by institutional investors and hedge funds. </p><h2>About Precigen</h2> (Get Free Report)<p>Precigen, Inc <span>NASDAQ: PGEN<span></span></span> is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen's approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.  </p><p>The centerpiece of Precigen's technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Precigen</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Do you know what Amazon is planning for January 1?</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Precigen Right Now?</h2><p>Before you consider Precigen, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.</p><p>While Precigen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PGEN

<p>Precigen (NASDAQ:PGEN) shares fell after insider selling by Director Randal J. Kirk, who sold 1.9 million shares. The stock opened at $4.17, down from the previous close of $4.38, and last traded at $4.03. Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy" and a price target of $8.50. Precigen focuses on genetic medicines and has a market cap of $1.43 billion.</p>

Precigen (NASDAQ:PGEN) Shares Gap Down Following Insider Selling